AZD8055 is a potent and selective inhibitor of the mTOR (mammalian target of rapamycin) kinase, targeting both mTORC1 and mTORC2 complexes. It is primarily used in cancer research to investigate signaling pathways involved in cell growth, proliferation, and survival. By blocking mTOR activity, AZD8055 demonstrates antitumor effects in various preclinical models, including breast, prostate, and lung cancers. Its ability to inhibit both mTOR complexes makes it a valuable tool for overcoming resistance seen with earlier mTOR inhibitors that only target mTORC1. AZD8055 has been used in studies exploring combination therapies with other anticancer agents, such as PI3K or AKT inhibitors, to enhance efficacy and suppress pathway reactivation. Due to its research applications, AZD8055 supports the development of targeted cancer therapies and helps elucidate the role of mTOR signaling in tumor progression and metabolism. It is not approved for clinical use but remains an important compound in oncology drug discovery.